Explore the latest in targeted and immune therapies, including recent advances in precision therapies and in use of tumor checkpoint inhibitors.
This nonrandomized phase 2 clinical trial examines the clinical activity of Olvi-Vec oncolytic immunotherapy and subsequent platinum-doublet chemotherapy with or without bevacizumab in women with platinum-resistant or -refractory ovarian cancers.
This meta-analysis of 3 randomized clinical trials evaluates the association of combined anti–PD-L1 agents with survival and response rate among patients with metastatic renal cell carcinoma.
This randomized clinical trial assesses progression-free survival among patients with RAS wild-type metastatic colorectal cancer receiving panitumumab plus standard-of-care trifluridine-tipiracil as third-line therapy.
This cohort study compares risk of death and major adverse cardiac and cerebrovascular events among patients with non–small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs) vs those not receiving TKIs in a nationwide cohort in Taiwan.
This cohort study of women with hormone receptor–positive metastatic breast cancer treated with targeted therapy in combination with endocrine therapy compares the outcomes for those with low vs no ERBB2 expression.
This case report describes a 28-year-old woman with Netherton syndrome who had large erythematous migratory patches with serpiginous double-edged scales on her face, neck, trunk, and extremities.
This case report describes a patient in their early 70s with sudden onset squeezing precordial chest pain, back pain, and nausea, and a history of long-term lung cancer treatment.
This cohort study evaluates tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy.
This systematic review with meta-analysis examines the regulatory oversight of the accelerated approval pathway and evidence generation for idelalisib during premarketing, postmarketing, and premarketing withdrawal periods.
This analysis of 3 randomized clinical trials assesses the efficacy and safety of upadacitinib to treat moderate-to-severe atopic dermatitis in adolescents.
This nonrandomized clinical trial investigates the addition of pembrolizumab to ifosfamide, carboplatin, and etoposide chemotherapy and evaluates the response rate of patients with relapsed or refractory Hodgkin lymphoma.
This nonrandomized clinical trial assesses the recommended phase 2 dose of regorafenib, ipilimumab, and nivolumab immunotherapy for patients with refractory microsatellite stable metastatic colorectal cancer.
This cohort study examines the association between habitual diet and response to treatment with immune checkpoint blockade among patients with advanced melanoma.
This cross-sectional study compares rates of molecular testing and targeted therapy among patients with non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) use by practice type and across practices.
This case report describes a 46-year-old woman presented with numerous monomorphic, mildly erythematous, and skin-colored smooth indurated papules that coalesced into plaques that involved the upper and lower eyelids, forehead, medial cheeks, cutaneous lips, and chin.
This review summarizes the current and evolving treatment landscape for platinum-resistant ovarian cancer and highlights the development of promising novel compounds.
This randomized clinical trial assesses the effect of adding panitumumab vs bevacizumab to standard first-line chemotherapy on overall survival among patients with RAS wild-type, left-sided, metastatic colorectal cancer.
Customize your JAMA Network experience by selecting one or more topics from the list below.